Celsion Enrolling Patients to Complete Phase 1 OVATION Clinical Trial

Celsion Enrolling Patients to Complete Phase 1 OVATION Clinical Trial
The independent Data Safety Monitoring Board has completed its safety review of data from the first four groups of the ongoing Phase 1 OVATION Study. As a result, Celsion Corporation can continue the study as planned and complete dosing the final group of patients. “The OVATION Study continues to progress on schedule and we look forward

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *